Comparative Pharmacology
Head-to-head clinical analysis: ESMOLOL HYDROCHLORIDE versus LABETALOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ESMOLOL HYDROCHLORIDE versus LABETALOL.
ESMOLOL HYDROCHLORIDE vs Labetalol
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective beta-1 adrenergic receptor antagonist; reduces heart rate, contractility, and blood pressure by blocking catecholamine effects at beta-1 receptors.
Labetalol is a racemic mixture of four stereoisomers, each with distinct activity. It is a non-selective beta-adrenergic antagonist (blocking beta1 and beta2 receptors) and a selective alpha1-adrenergic antagonist. The alpha1 blockade causes vasodilation and reduces peripheral vascular resistance, while beta blockade reduces heart rate and myocardial contractility, leading to decreased blood pressure without significant reflex tachycardia.
Loading dose: 500 mcg/kg IV over 1 minute, followed by maintenance infusion of 50 mcg/kg/min; titrate by 25-50 mcg/kg/min every 5-10 minutes up to 200 mcg/kg/min.
Oral: 200-1200 mg/day in 2 divided doses; initial 100 mg twice daily. IV: 20 mg bolus over 2 minutes, may repeat 40 mg at 10-minute intervals. Max cumulative dose: 300 mg.
None Documented
None Documented
Clinical Note
moderateLabetalol + Digitoxin
"Labetalol may increase the bradycardic activities of Digitoxin."
Clinical Note
moderateLabetalol + Deslanoside
"Labetalol may increase the bradycardic activities of Deslanoside."
Clinical Note
moderateLabetalol + Acetyldigitoxin
"Labetalol may increase the bradycardic activities of Acetyldigitoxin."
Clinical Note
moderateLabetalol + Ouabain
"Labetalol may increase the bradycardic activities of Ouabain."
Terminal elimination half-life: approximately 9 minutes in adults (range 4–13 min); in patients with hepatic impairment: unchanged; in severe renal impairment: prolonged to 12–20 min due to metabolite accumulation. Clinically, rapid offset (within 20–30 min) allows for titration.
6-8 hours (terminal elimination half-life); may be prolonged in hepatic impairment, unchanged in renal impairment.
Rapid metabolism by red blood cell esterases to inactive acid metabolite (ASL-8123) and methanol; <2% excreted unchanged in urine; primarily renal elimination of metabolites.
Renal (55-60% as unchanged drug and metabolites); biliary/fecal (minor, approximately 5-10%); remainder metabolized in liver.
Category A/B
Category A/B
Beta-Blocker
Alpha/Beta-Blocker